DLA Piper has advised the Austrian biotech company Panoptes Pharma on a recent capital increase. For the successfully closed financing round, aws Gründerfonds has become a shareholder.

The Vienna based biotech company Panoptes Pharma is focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. Among their greatest achievements is PP-001, a selective anti-inflammatory small molecule compound, which has demonstrated efficacy in a variety of preclinical models in ophthalmology.

The new funding will be primarily invested in the further development of PP-001 and the exploration of additional clinical indications in ophthalmology. aws Gründerfonds is one of Austria’s most active venture capital funds with a focus on young, highly scalable businesses.

DLA Piper has been advising Panoptes Pharma since their founding in the year 2013. The team advising on the recent capital increase was led by partner Christoph Mager and further included senior lead lawyer Johanna Höltl.

"I am pleased that we were able to support Panoptes once again with this this strategically important expansion. In the context of our specialised legal advice in the life sciences sector, it is our particular concern that ground-breaking developments can be appropriately financed and implemented", says Dr. Christoph Mager, partner and head of the Corporate group at DLA Piper in Vienna.